高剂量率近距离放疗联合外照射放疗治疗临床局限性前列腺癌
该研究纳入2008至2012年303例器官局限高危前列腺癌连续患者,接受高剂量率近距离放疗(HDR-BRT)后补充外照射放疗(EBRT)。中位随访71.6个月,7年总生存率85.7%、生化控制率88.3%、无转移生存率93.8%,晚期2级泌尿生殖毒性15.3%、3级2.2%、4级0.3%,晚期2级胃肠道毒性0.3%,无3级及以上晚期胃肠道不良事件。
要点
- 303例器官局限高危前列腺癌接受HDR-BRT(两次单次10.5 Gy植入,处方至腺体90% D90,总物理剂量21.0 Gy)后补充EBRT 45.0 Gy。
- 中位随访71.6个月,7年总生存率85.7%、生化控制率88.3%、无转移生存率93.8%。
- 晚期2、3、4级泌尿生殖不良事件分别为15.3%、2.2%、0.3%;晚期2级胃肠道毒性0.3%,无3级及以上晚期胃肠道不良事件。
核心结论
- HDR-BRT联合补充EBRT导致较低的生化无复发生存率,伴随极低的高级别晚期不良事件发生率。
研究设计与样本
- 2008年至2012年间,303例连续器官局限高危前列腺癌患者接受根治性放疗,包括HDR-BRT后补充EBRT。
主要发现
- 中位随访71.6个月,整个队列7年总生存率85.7%、生化控制率88.3%、无转移生存率93.8%。
- 92.7%的患者在治疗前开始雄激素剥夺治疗,中位持续时间12个月。
- 晚期2级、3级和4级泌尿生殖不良事件按事件计分分别为15.3%、2.2%和0.3%。
- 晚期2级胃肠道毒性占0.3%,无3级或更高晚期不良事件。
关键数值与推荐
- HDR-BRT boost采用经直肠3D超声引导下两次单次10.5 Gy植入,处方至腺体90%(D90),总物理剂量21.0 Gy。
- EBRT采用常规分割,处方45.0 Gy至前列腺和精囊。
- 生化失败根据Phoenix共识标准定义,泌尿生殖/胃肠道毒性采用不良事件通用术语标准(版本3.0)评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the clinical outcomes and treatment-related toxicities after combined high-dose-rate (HDR) brachytherapy (BRT) with external beam radiotherapy (EBRT) for patients with clinically localised high-risk prostate cancer. MATERIAL AND METHODS: Between 2008 and 2012, three hundred and three consecutive patients with organ-confined high-risk prostate cancer were treated with definitive radiotherapy consisting of HDR-BRT followed by supplemental EBRT. The transrectal 3D-ultrasound-based HDR-BRT boost consisted of two single-fraction implants of 10.5 Gy, prescribed to the 90% of the gland (D90), for a total physical dose of 21.0 Gy delivered to the prostatic gland. EBRT was delivered with conventional fractionation, prescribing 45.0 Gy to the prostatic gland and seminal vesicles. Biochemical failure was defined according to the Phoenix Consensus Criteria, genitourinary (GU)/gastrointestinal (GI) toxicity was evaluated using the Common Toxicity Criteria for Adverse Events (version 3.0). RESULTS: The median follow-up was 71.6 months. The 7-year overall survival, biochemical control and metastasis-free-survival rates for the entire cohort were 85.7%, 88.3% and 93.8%, respectively. Androgen deprivation therapy was initiated prior to treatment for 92.7% of patients with a median duration of 12 months. Toxicity was scored per event with late Grade 2, 3 and 4 GU adverse events and was found to be 15.3%, 2.2% and 0.3%, respectively. Late Grade 2 GI toxicity accounted for 0.3% with no instances of Grade 3 or higher late adverse events. CONCLUSION: HDR-BRT with supplemental EBRT results in low biochemical relapse-free survival rates associated with a very low incidence of higher-grade late adverse events.
引用
- Strouthos I, Chatzikonstantinou G, Zamboglou N, et al. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiother Oncol. 2018. PMID: 29764692. doi:10.1016/j.radonc.2018.04.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。